Wheeler DC, Toto RD, Stefansson BV, Jongs N, et al. A pre-specified analysis of the DAPA-CKD trial indicates effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021 Apr 17. pii: S0085-2538(21)00396.
PMID: 33878338